Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study

[1]  K. Schmiegelow,et al.  Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. , 2002, Medical and pediatric oncology.

[2]  K. Schmiegelow,et al.  Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system , 2001, British journal of haematology.

[3]  K. Schmiegelow,et al.  Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. , 2001, British journal of clinical pharmacology.

[4]  G. Gustafsson,et al.  Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation , 2000, Leukemia.

[5]  M. Relling,et al.  Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Weinshilboum,et al.  Possible carcinogenic effect of 6‐mercaptopurine on bone marrow stem cells , 1999, Cancer.

[7]  C. Pui,et al.  Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia , 1998, Leukemia.

[8]  V. Wahn,et al.  Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism. , 1985, Pediatric research.

[9]  J. Palmblad,et al.  Hypersensitive reactions and antibody formation during L‐asparaginase treatment of children and adults with acute leukemia , 1976, Cancer.

[10]  J. Bertino,et al.  L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. , 1971, Annals of internal medicine.

[11]  B. Asselin,et al.  The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. , 1999, Advances in experimental medicine and biology.